- Home
- KRRO vs FHTX Comparison
KRRO vs FHTX Comparison
Compare KRRO & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- FHTX
- Stock Information
- Founded
- KRRO 2014
- FHTX 2015
- Country
- KRRO United States
- FHTX United States
- Employees
- KRRO N/A
- FHTX N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- KRRO Health Care
- FHTX Health Care
- Exchange
- KRRO Nasdaq
- FHTX Nasdaq
- Market Cap
- KRRO 281.2M
- FHTX 237.4M
- IPO Year
- KRRO 2019
- FHTX 2020
- Fundamental
- Price
- KRRO $26.29
- FHTX $5.23
- Analyst Decision
- KRRO Strong Buy
- FHTX Strong Buy
- Analyst Count
- KRRO 7
- FHTX 6
- Target Price
- KRRO $133.83
- FHTX $13.17
- AVG Volume (30 Days)
- KRRO 61.9K
- FHTX 163.3K
- Earning Date
- KRRO 03-25-2025
- FHTX 03-06-2025
- Dividend Yield
- KRRO N/A
- FHTX N/A
- EPS Growth
- KRRO N/A
- FHTX N/A
- EPS
- KRRO N/A
- FHTX N/A
- Revenue
- KRRO N/A
- FHTX $25,515,000.00
- Revenue This Year
- KRRO N/A
- FHTX N/A
- Revenue Next Year
- KRRO N/A
- FHTX $8.30
- P/E Ratio
- KRRO N/A
- FHTX N/A
- Revenue Growth
- KRRO N/A
- FHTX N/A
- 52 Week Low
- KRRO $26.23
- FHTX $3.86
- 52 Week High
- KRRO $98.00
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- KRRO 29.17
- FHTX 52.39
- Support Level
- KRRO $28.90
- FHTX $3.89
- Resistance Level
- KRRO $40.68
- FHTX $6.27
- Average True Range (ATR)
- KRRO 2.26
- FHTX 0.59
- MACD
- KRRO -0.36
- FHTX 0.11
- Stochastic Oscillator
- KRRO 0.42
- FHTX 48.38
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.